Literature DB >> 2410689

Antiarrhythmic and electrophysiological effects of ICS 205-930, an antagonist of 5-hydroxytryptamine at peripheral receptors.

F M Williams, A L Rothaul, K A Kane, J R Parratt.   

Abstract

We assessed the antiarrhythmic activity of ICS 205-930 [(3 alpha-tropanyl)-1H-indole-3-carboxylic acid ester], a selective antagonist at neuronal 5-hydroxytryptamine M-receptors, against the arrhythmias that occur following occlusion of the left main coronary artery in anaesthetised rats and subsequent release (reperfusion). The incidence of reperfusion-induced ventricular fibrillation and ventricular tachycardia was significantly reduced by pretreatment with ICS 205-930 (0.3 and 1.0 mg kg-1 i.v. and 10 and 30 mg kg-1 p.o.). The arrhythmias that occurred during 30 min of coronary artery occlusion were also less severe in animals given ICS 205-930 (1.0 and 5.0 mg kg-1 i.v.). Arterial blood pressure was not altered by the drug, and heart rate was only slightly reduced by the highest intravenous dose. In vitro, ICS 205-930 reduced the maximum rate of rise of phase 0 of normal sheep Purkinje fibre action potentials in concentrations from 0.5 to 5.0 mg L-1. Action potentials depressed by superfusion with a physiological salt solution modified to mimic the conditions occurring during mild ischaemia were similarly affected by ICS 205-930. The highest drug concentration studied under these conditions was 1.5 mg L-1 since, in combination with the modified physiological salt solution, this rendered some of the Purkinje fibres inexcitable. These results indicate that ICS 205-930 possesses marked antiarrhythmic activity against ischaemia-induced arrhythmias in anaesthetised rats and that a direct electrophysiological effect of the drug may, at least in part, underlie its protective action.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2410689     DOI: 10.1097/00005344-198505000-00022

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  6 in total

1.  Evidence for inhibition by ICS 205-930 and stimulation by BRL 34915 of K+ conductance in cardiac muscle.

Authors:  G Scholtysik
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-06       Impact factor: 3.000

2.  Proceedings of the British Pharmacological Society. London, 19th-21st December. Abstracts.

Authors: 
Journal:  Br J Pharmacol       Date:  1989-03       Impact factor: 8.739

3.  Inhibition of the 5-HT-induced cardiogenic hypertensive chemoreflex by the selective 5-HT3 receptor antagonist ICS 205-930.

Authors:  H Berthold; G Scholtysik; G Engel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-03       Impact factor: 3.000

4.  Increased gut cholinergic activity and antagonism of 5-hydroxytryptamine M-receptors by BRL 24924: potential clinical importance of BRL 24924.

Authors:  G J Sanger
Journal:  Br J Pharmacol       Date:  1987-05       Impact factor: 8.739

5.  Block of the delayed rectifier current (IK) by the 5-HT3 antagonists ondansetron and granisetron in feline ventricular myocytes.

Authors:  F G de Lorenzi; T R Bridal; W Spinelli
Journal:  Br J Pharmacol       Date:  1994-10       Impact factor: 8.739

6.  Antiarrhythmic effects of DPI 201-106.

Authors:  G Scholtysik; F M Williams
Journal:  Br J Pharmacol       Date:  1986-10       Impact factor: 8.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.